138 related articles for article (PubMed ID: 37279427)
1. Severe acute respiratory syndrome coronavirus-2 antibody response after Moderna vaccine booster on healthcare providers.
Fachrucha F; Sutoyo DK; Nurwidya F; Andarini SL; Susanto AD; Isbaniah F; Handayani D; Yunus F; Soehardiman D; Zaini J; Saputri S; Prasenohadi
J Infect Dev Ctries; 2023 May; 17(5):617-622. PubMed ID: 37279427
[TBL] [Abstract][Full Text] [Related]
2. [COVID-19 infections and effectiveness of the vaccination among healthcare workers].
Rojkovich B; Németh D; Dinya E; Nagy E; Török E; Lázár I; Perduk A; Géher P; Nagy G
Orv Hetil; 2023 Feb; 164(5):163-171. PubMed ID: 36739547
[TBL] [Abstract][Full Text] [Related]
3. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
4. Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine.
Cucunawangsih C; Wijaya RS; Lugito NPH; Suriapranata I
Int J Infect Dis; 2022 May; 118():116-118. PubMed ID: 35192955
[TBL] [Abstract][Full Text] [Related]
5. Effects of Omicron Infection and Changes in Serum Antibody Response to Wild-Type, Delta, and Omicron After a Booster Dose With BNT163b2 Vaccine in Korean Healthcare Workers.
Lim SH; Kim HJ; Kim SH; Choi SH; Kim B; Kim JY; Ji YS; Kim T; Choo EJ; Jung JC; Moon JE; Kim CK; Park SK; Yun J
J Korean Med Sci; 2023 Apr; 38(13):e103. PubMed ID: 37012688
[TBL] [Abstract][Full Text] [Related]
6. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of antibody response after two doses of the Sinovac vaccine and the potential need for booster doses in cancer patients.
Ata S; Cil T; Duman BB; Unal N
J Med Virol; 2022 Jun; 94(6):2487-2492. PubMed ID: 35181932
[TBL] [Abstract][Full Text] [Related]
8. Durability of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Booster Vaccine Protection Against Omicron Among Healthcare Workers With a Vaccine Mandate.
Richterman A; Behrman A; Brennan PJ; O'Donnell JA; Snider CK; Chaiyachati KH
Clin Infect Dis; 2023 Feb; 76(3):e319-e326. PubMed ID: 35666508
[TBL] [Abstract][Full Text] [Related]
9. Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in Japan.
Igari H; Asano H; Murata S; Yoshida T; Kawasaki K; Kageyama T; Ikeda K; Koshikawa H; Okuda Y; Urushihara M; Chiba H; Yahaba M; Taniguchi T; Matsushita K; Yoshino I; Yokote K; Nakajima H
J Infect Chemother; 2022 Nov; 28(11):1483-1488. PubMed ID: 35870791
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
[TBL] [Abstract][Full Text] [Related]
11. The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis.
Zou Y; Huang D; Jiang Q; Guo Y; Chen C
Front Public Health; 2022; 10():940956. PubMed ID: 35910897
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Antibody Responses and Identification of Vaccine Breakthrough Infections Among Healthcare Workers Using Nucleocapsid Immunoglobulin G.
Anderson M; Stec M; Gosha A; Mohammad T; Boler M; Tojo Suarez R; Behun D; Landay A; Cloherty G; Moy J
J Infect Dis; 2022 Nov; 226(11):1934-1942. PubMed ID: 36263799
[TBL] [Abstract][Full Text] [Related]
13. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
Külper-Schiek W; Piechotta V; Pilic A; Batke M; Dreveton LS; Geurts B; Koch J; Köppe S; Treskova M; Vygen-Bonnet S; Waize M; Wichmann O; Harder T
Front Immunol; 2022; 13():940562. PubMed ID: 36091023
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.
Canaday DH; Oyebanji OA; White EM; Bosch J; Nugent C; Vishnepolskiy I; Abul Y; Didion EM; Paxitzis A; Sundheimer N; Ragavapuram V; Wilk D; Keresztesy D; Cao Y; St Denis K; McConeghy KW; McDonald LC; Jernigan JA; Mylonakis E; Wilson BM; King CL; Balazs AB; Gravenstein S
MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(4):100-106. PubMed ID: 36701254
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Anti-SARS-CoV-2 antibody levels among university students vaccinated with different COVID-19 primary and booster doses - fall 2021, Wisconsin.
DeJonge PM; Lambrou AS; Segaloff HE; Bateman A; Sterkel A; Griggs C; Baggott J; Kelly P; Thornburg N; Epperson M; Desamu-Thorpe R; Abedi G; Hsu CH; Nakayama JY; Ruffin J; Turner-Harper D; Matanock A; Almendares O; Whaley M; Chakrabarti A; DeGruy K; Daly M; Westergaard R; Tate JE; Kirking HL
BMC Infect Dis; 2023 Jun; 23(1):374. PubMed ID: 37277736
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 Antibody Response and Sustainability after a Third Dose of BNT162b2 in Healthcare Workers at Health Promotion Centers.
Nah EH; Cho S; Park H; Kim S; Noh D; Kwon E; Cho HI
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992460
[TBL] [Abstract][Full Text] [Related]
17. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial.
Thakkar A; Pradhan K; Duva B; Carreno JM; Sahu S; Thiruthuvanathan V; Campbell S; Gallego S; Bhagat TD; Rivera J; Choudhary G; Olea R; Sabalza M; Shapiro LC; Lee M; Quinn R; Mantzaris I; Chu E; Will B; Pirofski LA; Krammer F; Verma A; Halmos B
Elife; 2023 Mar; 12():. PubMed ID: 36975207
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
19. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
[TBL] [Abstract][Full Text] [Related]
20. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
